International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE	THE PSYCHEDELIC AND KETAMINE RENAISSANCE IN THE FACE OF THE CRISIS IN MODERN PSYCHIATRY
DOI	https://doi.org/10.31435/ijitss.2(50).2026.5605
RECEIVED	13 February 2026
ACCEPTED	04 June 2026
PUBLISHED	15 June 2026
LICENSE	The article is licensed under a **Creative Commons Attribution 4.0 International License.**

THE PSYCHEDELIC AND KETAMINE RENAISSANCE IN THE FACE OF THE CRISIS IN MODERN PSYCHIATRY

Julia Osipowska *(Corresponding Author, Email: josipowska@gmail.com)*
University Clinical Hospital No. 1 in Lublin, Lublin, Poland
ORCID ID: 0009-0007-9024-9908

Marlena Kwolek
University Clinical Hospital No. 4 in Lublin, Lublin, Poland
ORCID ID: 0009-0004-1428-1103

Alicja Judzińska
University Clinical Hospital No. 1 in Lublin, Lublin, Poland
ORCID ID: 0009-0007-7525-4012

Bartosz Piech
University Clinical Hospital No. 1 in Lublin, Lublin, Poland
ORCID ID: 0009-0003-4621-5226

Kamila Sobczyńska
Stefan Cardinal Wyszyński Provincial Specialist Hospital in Lublin, Lublin, Poland
ORCID ID: 0009-0002-0938-1711

Justyna Ignarska
University Clinical Hospital No. 4 in Lublin, Lublin, Poland
ORCID ID: 0009-0009-0340-8240

Magda Terbosh
University Clinical Hospital No. 1 in Lublin, Lublin, Poland
ORCID ID: 0009-0006-3756-3394

Sabina Kubicz Mzabi
University Clinical Hospital No. 4 in Lublin, Lublin, Poland
ORCID ID: 0009-0008-2788-5538

Emilia Trojanowska
SP ZOZ MSWiA in Lublin, Lublin, Poland
ORCID ID: 0009-0009-7331-6624

Magdalena Dubaj
University Clinical Hospital No. 1 in Lublin, Lublin, Poland
ORCID ID: 0009-0005-4429-2679

ABSTRACT

Introduction: Contemporary psychiatry is grappling with a profound stagnation in innovation. It is primarily relying on the chronic management of symptoms through traditional daily-dose pharmacotherapy. The emergence of psychedelics and ketamine marks a significant departure from this model. It is offering rapid-acting, interventional alternatives that target the underlying neurobiological mechanisms of mental disorders rather than mere symptom suppression.
Purpose: The primary objective of this article is to evaluate the therapeutic potential of psychedelics and ketamine as catalysts for a new paradigm in mental healthcare. The paper aims to synthesize current knowledge on 5-HT2A receptor agonism, the development of next-generation non-hallucinogenic psychoplastogens, and the ethical-legal challenges associated with implementing these treatments in the global and Polish healthcare systems.
Methodology: This study employs a multidisciplinary literature review, integrating recent findings from neuropsychopharmacology, clinical trial outcomes, and bioethical analysis. It compares the efficacy and administration models of classic psychedelics against conventional treatments (e.g., SSRIs) and examines the socioeconomic factors influencing the democratization of these therapies.
Conclusions: The "psychedelic renaissance" necessitates the adoption of a new language for psychiatry, rooted in neuroplasticity and connectivity. To achieve widespread scalability, the field must focus on isolating the plasticity effect and utilizing short-acting tryptamines to reduce clinical resource burdens. Furthermore, for Poland to actively participate in this medical revolution, urgent legislative harmonization and robust ethical frameworks regarding patient suggestibility are required.

KEYWORDS

Depression, Psychedelics, Ketamine, Psylocybin, 5-HT2A agonism, Neuroplasticity, Bioethics, Mental Health

CITATION

Julia Osipowska, Marlena Kwolek, Alicja Judzińska, Bartosz Piech, Kamila Sobczyńska, Justyna Ignarska, Magda Terbosh, Sabina Kubicz Mzabi, Emilia Trojanowska, Magdalena Dubaj. (2026) The Psychedelic and Ketamine Renaissance in the Face of the Crisis in Modern Psychiatry. *International Journal of Innovative Technologies in Social Science*. 2(50). doi: 10.31435/ijitss.2(50).2026.5605

Introduction.

The modern psychiatry, despite having developed the effective ways of treating various mental disorders, is still facing many obstacles. One of the most significant ones, is treatement-resistant depression.

For the last six decades the dominant treatment model for depressive disorders was based almost exclusively on the so-called monoamine hypothesis [1]. It was a concept that fundamentally reshaped our understanding of the pathogenesis and treatment of affective disorders. The first hypothesis, centered on the role of catecholamines (norepinephrine and dopamine), was presented in 1965 [2]. The serotonin hypothesis of depression was presented in 1969 [3]. These theories remain the cornerstones of psychiatry and psychopharmacology. The clinical application of these theories led to the development of the most currently available antidepressants, which target monoamine neurotransmitter function [4]. Selective Serotonin Reuptake Inhibitors (SSRIs) represent the current gold standard in antidepressant pharmacotherapy. The launch of fluoxetine (Prozac) in the United States during the late 1980s and early 1990s was more than a medical milestone, it was a profound cultural phenomenon [5]. By the 21st century, serotonin had transitioned from a laboratory focus to a public icon, widely romanticized in literature and popular media as the „happiness hormone". The SSRIs had become the most frequently prescribed psychoactive drugs in human history [1].

However, 21st century epidemiological data present a sobering challenge to the efficiacy of the monoamine model. Despite the expenditure of billions of dollars on pharmacotherapy and the consumption of vast quantities of antidepressants, global depression rates show no signs of decline [26]. On the contrary, prevalence is rising sharply, with the World Health Organization (WHO) identifying depression as the leading cause of disability worldwide [6,7].

Furthermore, a significant clinical cohort—estimated at 30% to 40% of patients—exhibits Treatment-Resistant Depression (TRD). TRD is formally defined as a failure to achieve clinically significant remission following at least two adequate trials of different antidepressant classes. For these individuals, the traditional psychiatric approach of daily serotonergic modulation has reached a therapeutic plateau, often resulting in burdensome side effects without the promised symptomatic relief [8,9].

Part 1: Why the SSRIs are not enough?

1.1. The criticism of monoamine theory

To elucidate the clinical requirement for new approach in treating depression, one must first conduct a rigorous deconstruction of the structural inconsistencies within the prevailing psychiatric model. For decades, the dominant clinical discourse posited that depressive phenotypes were the direct physiological consequence of a serotonergic deficyte [1].

However, the empirical foundation of this model was fundamentally challenged by a comprehensive umbrella review conducted by Moncrieff et al. (2022) in Molecular Psychiatry. This meta-analysis of decades of high-level data concluded that there is no statistically significant evidence to support a causal link between lowered serotonin concentrations (or activity) and the pathogenesis of depression. The study revealed no consistent disparities in serotonin metabolites or receptor binding potential between depressed cohorts and healthy control groups. These findings necessitate a critical re-evaluation of Selective Serotonin Reuptake Inhibitors (SSRIs) as targeted pharmacological agents. The data suggests that the therapeutic efficacy of SSRIs—where observed—does not derive from the correction of a localized biochemical deficiency. Instead, their impact likely stems from broader, non-specific physiological modulations or a delayed, secondary induction of neuroplasticity. Consequently, the reliance on chronic monoaminergic modulation is increasingly categorized as a pharmacological oversimplification, proving insufficient for a significant portion of the clinical population and mandating a transition toward more robust, rapid-acting neurobiological catalysts [10,11,12].

1.2. The problem of synaptic delay and plasticity

One of the most significant clinical limitations of conventional antidepressants is the prolonged therapeutic latency (the therapeutic window). While systemic serotonin levels increase almost immediately upon administration, clinically significant improvements in mood, psychomotor drive, and cognitive function typically manifest only after 4–6 weeks, or even up to two months. This temporal paradox suggests that the presence of the neurotransmitter itself is not the primary curative agent. Rather, the therapeutic effect is a secondary result of slow, downstream neuroadaptive processes [13].

Modern neurobiology, pioneered by the work of Ronald Duman and expanded by recent molecular research, posits that depression is not a biochemical deficit, but a physical loss of synaptic connectivity [14]. Under the conditions of chronic stress and hypercortisolemia, neurons in critical regions—specifically the hippocampus (regulating memory and affect) and the prefrontal cortex (executive function)—undergo dendritic atrophy. This leads to a reduction in neural density and a diminished capacity for cognitive and emotional flexibility [15]. Conventional SSRIs facilitate the restoration of these connections through a sluggish and often inefficient pathway, failing to provide the rapid structural reorganization required for acute clinical remission [16].

1.3. Default Mode Network (DMN)

A further critical factor in the failure of conventional pharmacotherapy for severe depressive phenotypes is the dysregulation of the Default Mode Network (DMN). This large-scale neural network—centered primarily in the posterior cingulate cortex (PCC) and the medial prefrontal cortex (mPFC)—exhibits peak metabolic activity during internally directed cognition, such as self-referential processing, episodic memory retrieval, and future-oriented mental oversight [17, 19].

In clinical depression, the DMN becomes pathologically hyperactive and characterized by neurodynamic rigidity. This state serves as the biological substrate for „internal criticism" and rumination—the intrusive, repetitive, and maladaptive processing of negative self-schema [18, 19]. Conventional antidepressants rarely exert sufficient modulatory influence to recalibrate this network, leaving patients cognitively sequestered within established negative thought loops despite chemical intervention. In contrast, serotonergic psychedelics function as a biological „circuit breaker", inducing a transient state of network desynchronization that facilitates a systemic reset of neural connectivity [20, 21].

Part 2: The History of Forbidden Science

2.1. Golden era of research

The medical trajectory of psychedelic originated in the laboratories of the Swiss pharmaceutical company Sandoz. Following Albert Hofmann's accidental discovery of LSD-25's psychoactive properties in 1943, the substance became the subject of the most intensive psychiatric investigation of the mid-20th century [22].

Visionary clinicians, including Humphry Osmond—who etymologically derived the term „psychedelic" from the Greek psyche (mind/soul) and delos (to manifest)—and Stanislav Grof, conceptualized these agents as psychopharmacological tools comparable to the microscope in biology. They facilitated a direct interface with subconscious structures that traditionally required years of psychoanalytic intervention [23, 24]. The clinical outcomes in treating Alcohol Use Disorder (AUD) were statistically profound. Recovery rates reached nearly 50%, a benchmark that remains largely unsurpassed by contemporary standarized interventions [25].

2.2. Years of silence

The cessation of research on psychedelics was precipitated not by clinical failure, but by geopolitical and sociological exigencies. The convergence of the counterculture movement, anti-war sentiment, and the controversial advocacy of figures such as Timothy Leary transformed psychedelics into potent symbols of systemic defiance [27]. In 1970, the Nixon administration enacted the Controlled Substances Act, categorizing LSD and psilocybin as Schedule I substances. This designation is explicitly reserved for agents with „a high potential for abuse and no currently accepted medical use" [28].

This was fundamentally an ideological mandate rather than a medical one. It resulted in a several-decade moratorium on formal scientific inquiry, effectively freezing the evolution of psychedelic medicine. This legislative blockade relegated millions of patients to suboptimal treatment modalities, halting the development of rapid-acting neurobiological interventions in favor of the burgeoning—but ultimately limited—monoamine-based pharmaceutical model [29].

Part 3: Ketamine and NMDA

While classic psychedelics remained legally and clinically sequestered, ketamine emerged as the „dark horse" of biological psychiatry, fundamentally altering the therapeutic landscape from within the controlled environment of surgical suites [30]. Utilized since the 1960s as a high-safety profile anesthetic—distinguished by its preservation of respiratory drive, making it indispensable in emergency and pediatric medicine [31]—ketamine has demonstrated unprecedented efficacy as a rapid-acting antidepressant when administered at sub-anesthetic doses [30, 33].

3.1. The blockade of the NMDA receptors

The pharmacological profile of ketamine represents a fundamental paradigm shift from monoaminergic modulation to glutamatergic intervention. Ketamine functions as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor. Rather than the gradual elevation of systemic serotonin, ketamine acts directly upon the glutamatergic system—the primary excitatory neurotransmitter network in the central nervous system [34].

By selectively blocking NMDA receptors located on specific inhibitory GABAergic interneurons, ketamine triggers a paradoxical downstream effect known as disinhibition. This process effectively „releases the brakes" on excitatory signaling, resulting in a rapid, transient surge of glutamate, a phenomenon described in the literature as a „glutamate burst" [37]. This acute surge serves as a high-velocity neurobiological signal that initiates a cascade of intracellular reparative processes.

The most critical of these is the activation of the mTOR (mammalian target of rapamycin) pathway. As demonstrated in the seminal study by Li et al. (2010) in Science, this „glutamate burst" stimulates the rapid synthesis of synaptic proteins, leading to the physical reconstruction of dendritic spines in the prefrontal cortex within hours [39]. This immediate synaptogenesis explains why ketamine can induce clinical remission in treatment-resistant populations where traditional SSRIs have failed. Unlike the weeks-long therapeutic latency of conventional antidepressants, ketamine bypasses the slow monoamine system to directly target the structural integrity of neural networks [38].

3.2. Neuroplasticity and BDNF protein

The primary physiological consequence of the „glutamate burst" is the acute activation of the mTOR (mammalian target of rapamycin) signaling pathway and the subsequent upregulation of Brain-Derived Neurotrophic Factor (BDNF) expression. BDNF serves as a critical neurotrophic catalyst, facilitating the survival and growth of existing neurons. Brain-Derived Neurotrophic Factor is a protein encoded by the BDNF gene and belongs to the neurotrophin family of growth factors. It is the primary regulator of synaptic plasticity, promoting the survival of existing neurons and encouraging synaptogenesis and differentiation of new neurons and synapses [40].

The Ketamine-BDNF Cascade

In the context of rapid-acting antidepressants, BDNF acts as the essential „bridge" between the initial glutamate burst and the physical repair of the brain. The mechanism follows a precise molecular sequence:

1. Glutamate-Driven Release: The transient surge of glutamate induced by NMDA receptor antagonism leads to the activation of AMPA receptors. This depolarization triggers the activity-dependent release of stored BDNF vesicles into the synaptic cleft [41].
2. TrkB Receptor Activation: Secreted BDNF binds with high affinity to its cognate receptor, Tropomyosin receptor kinase B (TrkB).
3. Intracellular Signaling (mTOR): The activation of TrkB triggers the PI3K-Akt-mTOR signaling pathway. This pathway is responsible for the rapid translation of synaptic proteins (such as PSD-95 and GluA1), which are the physical building blocks of new dendritic spines [39].

BDNF as a Biomarker of Depression and Recovery

Chronic stress and hypercortisolemia lead to a significant downregulation of BDNF expression, particularly in the hippocampus and medial prefrontal cortex (mPFC). This deficiency results in the structural atrophy observed in depressive phenotypes [42].

The revolutionary nature of ketamine and psychedelics lies in their ability to bypass traditional, slow genomic pathways. While SSRIs take weeks to indirectly increase BDNF levels through chronic serotonergic modulation, ketamine induces an immediate release of BDNF pools, facilitating a structural „reset" of atrophied circuits within hours [43]. Notably, recent evidence suggests that the direct binding of antidepressants (including ketamine and potentially psychedelics) to the TrkB receptor may be the fundamental mechanism underlying their clinical efficacy, independent of traditional neurotransmitter signaling [43].

Histological and neuroimaging investigations—pioneered by research teams at Yale University—have demonstrated that within a window of 2 to 24 hours following a single sub-anesthetic dose of ketamine, the prefrontal cortex undergoes rapid structural remodeling, specifically:

1. Dendritic Spine Proliferation: Atrophied neural connections exhibit physical „regrowth," effectively reversing stress-induced synaptic loss [39].
2. Synaptogenesis: The formation of novel functional synaptic interfaces between neurons.

This mechanism elucidates the rapid-acting antidepressant (RAAD) properties of ketamine. Unlike conventional pharmacotherapy, which relies on gradual neuroadaptive changes, ketamine initiates a physical restoration of neural „wiring" within a single diurnal cycle, bypassing the prolonged therapeutic latency associated with monoaminergic drugs [35].

3.3. Esketamine

In 2019, following a series of successful clinical trials, the Food and Drug Administration (FDA) granted regulatory approval for esketamine—the S-enantiomer of the ketamine molecule—in the form of an intranasal spray (marketed as Spravato). This intervention is strictly indicated for patients diagnosed with Treatment-Resistant Depression (TRD), defined by a lack of clinical response to at least two different classes of antidepressants [44].

Following a comprehensive meta-analysis of clinical trials evaluating the efficacy, tolerability, and safety of intranasal esketamine in the treatment of Major Depressive Disorder (MDD), it was demonstrated that intranasal esketamine exhibits ultra-rapid antidepressant effects that persist for at least 28 days [26]. Another meta-analysis encompassing multiple randomized controlled trials (RCTs) concluded that adjunctive intranasal esketamine represents an effective treatment strategy for patients with Treatment-Resistant Depression [26].

The European Medicines Agency (EMA) has approved esketamine nasal spray for use in combination with a Selective Serotonin Reuptake Inhibitor (SSRI) or a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) for adults suffering from treatment-resistant forms of depression [26].

Part 4: Psylocybin

While ketamine functions primarily as a „biological repair agent" targeting glutamatergic pathways, psilocybin—the primary psychoactive alkaloid in Psilocybe mushrooms—reintroduces a dimension long marginalized by modern psychiatry: the significance of the subjective existential experience.

Research led by Robin Carhart-Harris and the team at Johns Hopkins University suggests that in psilocybin-assisted therapy, the phenomenological content of the session—what the patient feels, perceives, and internalizes—is an integral component of the therapeutic mechanism rather than a mere pharmacological „side effect" [45]. Clinical outcomes, particularly in treatment-resistant depression, have been shown to correlate strongly with the intensity of the „mystical-type experience", characterized by a sense of unity, transcendence, and deeply felt positive affect [46]. This suggests that psilocybin acts as a catalyst for a profound cognitive and emotional reorganization, providing a biological window for psychological insight.

4.1. 5-HT2A receptor agonism

Upon ingestion, psilocybin is rapidly dephosphorylated in the liver by alkaline phosphatase into its active metabolite, psilocin. Due to its structural homology with the endogenous neurotransmitter serotonin (5-HT), psilocin exhibits high binding affinity for 5-HT2A receptors, which are most densely concentrated in the pyramidal neurons of the neocortex—the most evolutionarily advanced region of the human brain [47].

The stimulation of these receptors triggers a profound shift in neural dynamics. Neurobiology observes a reduction in modularity and a disruption of rhythmic oscillations (specifically in the alpha band) within high-level association cortices. As demonstrated by researchers at Imperial College London, this results in the functional disintegration of the Default Mode Network (DMN)—the system responsible for self-referential cognition and ruminative thought patterns [48].

In the depressive brain, the DMN is characterized by pathological hyper-connectivity and rigidity. Psilocybin facilitates a transient state of network desynchronization, which patients experience as „ego dissolution". This collapse of the internal self-schema allows for a temporary suspension of maladaptive cognitive biases, enabling an objective re-evaluation of emotional traumas without the interference of the brain's typical defensive filters [49].

4.2. Global connectivity

The most profound observation in functional Magnetic Resonance Imaging (fMRI) studies of the psychedelic state is a radical reconfiguration of inter-regional communication. Under baseline conditions, the human brain exhibits a highly modular architecture, where functionally specialized clusters (e.g., the visual cortex or the motor system) operate with high internal connectivity but limited interaction with distant, non-homologous regions [50].

In the psychedelic state induced by psilocybin, these modular boundaries undergo a transient collapse. Regions associated with emotional processing, long-term memory, and sensory perception begin to form thousands of novel, cross-modular functional links. This phenomenon, often visualized as a massive expansion of the brain’s connectome, represents a transition from a constrained, hierarchical communication model to a highly integrated, global network [51].

This acute increase in global integration provides the biological substrate for cognitive insight. By facilitating communication between previously isolated neural circuits—such as those storing traumatic memories and those regulating high-level executive function—psilocybin enables patients to achieve profound insights. This allows for the integration of past facts with present emotional states, bypassing the rigid cognitive filters that typically characterize depressive pathology [49].

Part 5: "Set & Setting" model

It is vital to distinguish between „recreational use" and Psychedelic-Assisted Psychotherapy (PAP). In professional psychiatry, the psychedelic substance functions exclusively as a catalyst for psychological change. The core therapeutic work occurs within a rigorous clinical protocol developed by institutions such as MAPS (Multidisciplinary Association for Psychedelic Studies) and Compass Pathways [52].

Under the PAP model, the drug is not administered as a stand-alone chronic treatment. Instead, it is embedded within a structured psychotherapeutic framework consisting of three distinct phases: preparation, dosing, and integration. This methodology is designed to minimize psychological risks—such as acute anxiety or „bad trips"—while maximizing the therapeutic potential of the induced state of heightened neuroplasticity [53].

The efficacy of this model relies on the synergy between the pharmacological action of the substance and the professional therapeutic alliance, ensuring that the profound subjective experiences are safely processed and translated into lasting behavioral and cognitive changes [45].

Part 6: Safety and Ethics

Despite the therapeutic potential of ketamine and psilocybin, they are not universal solutions. The established safety protocols for psychedelic and dissociative therapies mandate strict exclusion criteria to prevent severe adverse psychiatric or physiological events.

6.1. Psychiatric and cardiological contraindications

The most rigorous contraindication for 5-HT2A receptor agonists (such as psilocybin) is a personal or first-degree familial history of psychosis, schizophrenia, or Bipolar I Disorder (specifically manic episodes). Potent stimulation of these receptors in genetically predisposed individuals can precipitate a prolonged psychotic episode or trigger latent mania that may be refractory to standard interventions [54]. Clinical trials consistently exclude these populations to maintain the highest safety margins.

Regarding ketamine (and esketamine), the primary contraindications are physiological due to its sympathomimetic effects. Ketamine administration causes a transient but significant increase in systolic and diastolic blood pressure and heart rate [55]. Consequently, patients with the following conditions are strictly excluded from treatment: uncontrolled hypertension, history of intracranial or aortic aneurysms, recent myocardial infarction (heart attack) [56].

6.2. The risk of HPPD and „bad trip”

While statistically rare—occurring in fewer than 1% of clinical trial participants—Hallucinogen Persisting Perception Disorder (HPPD) is a documented phenomenon. It is characterized by enduring visual disturbances, such as „visual snow", halos, or trailing, which persist long after the substance has been metabolized [57].

Furthermore, the profound psychological vulnerability induced by psychedelics can lead to acute psychological distress or „bad trips". Without the presence of trained experts to provide containment and support, these difficult emotional experiences can result in secondary traumatization rather than the intended therapeutic breakthrough [58].

This underscores the critical necessity of distinguishing regulated, evidence-based medicine from self-medication with illicit substances, where the absence of a controlled "Set and Setting" significantly escalates the risk of adverse outcomes [54].

6.3. Ethical Challenges: Suggestibility

During the peak of a psychedelic-assisted session, the patient enters a state of extreme psychological suggestibility and profound emotional openness [59]. This pharmacological „opening" is the very mechanism that allows for the dismantling of rigid depressive schemas, but it simultaneously creates a state of extreme psychological vulnerability.

The history of unregulated or „underground" therapy is marred by instances where this vulnerability was exploited, leading to boundary violations and secondary trauma. Consequently, the implementation of stringent clinical certification and a specialized code of ethics—such as the framework developed by the Multidisciplinary Association for Psychedelic Studies (MAPS)—is the only viable pathway to ensure patient protection. Standard protocols now mandate the presence of co-therapists (often a gender-balanced dyad) and rigorous training in „non-directive" support to mitigate the risks associated with this unique state of susceptibility [53].

Part 7: Psychedelics vs. Conventional Pharmacotherapy

The divergence between traditional pharmacology and psychedelic therapy represents a fundamental shift in the philosophy of care. This is best understood by contrasting the „Maintenance" model of SSRIs with the „Interventional" model of PAP.

Standard treatment with Selective Serotonin Reuptake Inhibitors (SSRIs) is based on chronic, daily administration. It aims to increase synaptic serotonin levels over time, which often results in a „top-down" emotional regulation.

The "Emotional Blunting" Effect: A documented side effect of chronic SSRI use is a reduction in the intensity of both negative and positive emotions. Patients often describe this as „feeling numb" rather than „feeling better" [60]. The treatment is designed for long-term stabilization, frequently lasting years, with symptoms often returning upon discontinuation.

In contrast, Psychedelic-Assisted Psychotherapy (PAP) operates as a short-term, high-intensity intervention. Instead of chronic modulation, it uses 1–3 high-dose sessions to trigger an acute „window of neuroplasticity."

In a landmark study published in the New England Journal of Medicine, researchers compared psilocybin directly with escitalopram. While both reduced depressive symptoms, psilocybin showed superior results in secondary measures such as the ability to feel pleasure (hedonia) and social connectedness [61]. The aim is a „reboot" of neural networks, leading to sustained remission without the need for daily medication.

7.1. Side effects

The primary limitation of traditional antidepressants is not necessarily a lack of efficacy (as they function adequately for many patients), but rather the systemic „price" paid for daily administration.

Emotional Blunting

Research indicates that SSRIs often cause emotional blunting. While they effectively mitigate extreme despair, they simultaneously attenuate the capacity for profound joy, awe, and empathy. Patients frequently report that their subjective world becomes „flat and grey" [60]. In contrast, the study in the New England Journal of Medicine demonstrated that psilocybin-treated patients reported a return of the full affective range. Instead of blunting, they experienced a restored capacity for cathartic crying and a deep sense of connectedness to nature and others [61].

Sexual Dysfunction and Metabolic Impact

Adverse effects on sexual health affect up to 60% of patients on classic antidepressants [62]. This drastically reduces self-esteem and strains interpersonal relationships, often leading to non-compliance and unauthorized discontinuation. Furthermore, metabolic weight gain remains one of the leading reasons for treatment abandonment [63].

Transient vs. Chronic Side Effects

A critical distinction lies in the duration of adverse events. While SSRI side effects are often chronic and pervasive, those associated with psilocybin—such as transient nausea or headaches—are typically limited to the dosing day itself. This allows for a „cleaner" recovery period where the brain is free from daily pharmacological interference [61].

7.2. Dosing schedule

Traditional psychiatry has long been built upon the principle of chronicity—the continuous pharmacological management of symptoms. In contrast, Psychedelic-Assisted Psychotherapy (PAP) introduces the concept of point-intervention.

Clinical data indicates that just one or two high-dose sessions of psilocybin can induce significant clinical remission lasting from 6 to 12 months [64]. From a neurobiological perspective, this approach offers a revolutionary advantage: it provides the brain with an extended window to function naturally, driven by endogenous neurotransmission rather than the constant presence of exogenous chemicals.

By triggering a transient but powerful state of neuroplasticity (marked by increased BDNF expression), these interventions allow for a structural and functional „reset" of neural networks [65]. This shift from daily suppression to episodic transformation represents a fundamental revolution in how we conceptualize the treatment of mental disorders—moving toward a model of long-term healing rather than lifelong dependency [66].

Part 8: Microdosing

Microdosing is defined as the intermittent ingestion of psychedelic substances (typically psilocybin or LSD) at sub-hallucinogenic doses—usually 5% to 10% of a standard therapeutic dose. Unlike full-dose therapy, microdosing does not aim to induce an altered state of consciousness but seeks to modulate cognitive and emotional functioning over time [67].

8.1. Mechanisms and Protocols

The most common administration framework is the Fadiman Protocol, which involves a „one day on, two days off" cycle to prevent receptor down-regulation (tolerance). Proponents of this method report improvements in executive function, sustained attention, and emotional regulation, often positioning it as a potential alternative to traditional stimulants or SSRIs for the management of ADHD and mild depressive symptoms [67].

8.2. The Placebo Challenge in "Citizen Science"

Despite widespread anecdotal support, recent controlled studies have challenged the perceived efficacy of microdosing. A landmark „self-blinding" study by Szigeti et al. (2021), involving nearly 200 participants, found that while users reported significant psychological benefits, the placebo group showed nearly identical improvements across all primary measures. These results suggest that the „microdosing effect" may be heavily mediated by positive expectancy rather than pharmacological action at such low concentrations [68].

8.3. Sub-threshold Neuroplasticity

However, the lack of immediate psychological separation from placebo does not rule out long-term neurobiological changes. Laboratory research confirms that even sub-threshold doses of 5-HT2A agonists promote synaptogenesis and increase dendritic spine density in the prefrontal cortex. This suggests that while the acute „biohacking" effect may be placebo-driven, microdosing might function as a long-term „neurotrophic primer," potentially requiring extended protocols or synergy with behavioral therapy to yield statistically significant clinical outcomes [65].

Part 9: Geopolitics, Law, and Economics – Where does Poland stand?

The transition toward psychedelic-assisted therapies is increasingly driven by macroeconomic necessity. The global cost of depression and mental health disorders is currently measured in trillions of dollars, accounting for lost workplace productivity, long-term disability payments, and the immense burden of chronic hospitalization [69]. In the United States alone, the economic burden of Major Depressive Disorder (MDD) was estimated at $382,4 billion in 2023 [70].

9.1. Global Regulatory Shifts vs. the Polish Context

While nations like Australia (which, as of July 1, 2023, allows authorized psychiatrists to prescribe psilocybin and MDMA) [71] and U.S. states such as Oregon and Colorado are leading the regulatory vanguard [72,73], the European landscape remains fragmented.

In Poland, the legal framework remains highly restrictive. Psilocybin and MDMA are still classified under the Act on Counteracting Drug Addiction in group I-P [74], which traditionally implies high abuse potential and no medical value. However, Poland stands at a geopolitical and clinical crossroads due to two major factors:

The "Esketamine Precedent": Esketamine (Spravato) is available in clinics across Poland for treating the treatment-resistant depression under a specific drug reimbursement program [75,76].

EMA Pressure: The European Medicines Agency (EMA) held a landmark multi-stakeholder workshop in 2024 specifically to outline the regulatory path for psychedelics, signaling that a centralized European approval is a matter of „when", not „if" [77].

The integration of Psychedelic-Assisted Psychotherapy (PAP) into the Polish national healthcare system would require not only a legislative shift in the classification of controlled substances but also a massive investment in certified therapist training and clinical safety protocols.

Part 10: Psychedelics without „trip”?

The debate in modern neurobiology has shifted toward a fundamental question: is the „mystical experience" a clinical necessity, or merely a side effect of a biochemical cascade?

10.1. Isolating the Plasticity Effect: Next-Generation Molecules

Laboratories worldwide are developing non-hallucinogenic psychedelic analogs. The objective is to trigger neuroplasticity without the altered state of consciousness.

Tabernanthalog (TBG): A synthetic, non-hallucinogenic derivative of ibogaine. Research on animal models demonstrated that TBG promotes the growth of dendritic spines and exerts antidepressant effects without the cardiac toxicity or „head-twitch response" (a behavioral proxy for hallucinations) [78]. These "plasticity primers" could potentially be taken at home without a therapist's supervision, drastically lowering the cost of treatment and increasing accessibility [79].

Clinicians at institutions like Johns Hopkins University argue that „subjective insight" and emotional breakthroughs are what guarantee the longevity of change. Without the „trip", the brain might become biologically more flexible, but the patient remains without the psychological tools to process their trauma [80].

10.2. Rapid-acting tryptamines

While psilocybin requires a 6–8 hour commitment, new research focuses on molecules that offer a „compact" therapeutic window. 5-MeO-DMT is known for inducing one of the most intense psychedelic experiences, which last only 20 to 40 minutes [81]. From a hospital management perspective, short-acting compounds allow for multiple sessions per day in a single treatment room. This significantly increases the scalability of Psychedelic-Assisted Psychotherapy (PAP), making it more attractive for public healthcare systems.

Companies like Beckley Psytech are currently conducting Phase I clinical trials assessing the safety, tolerability, and pharmacokinetics of single ascending doses of a 5-MeO-DMT intranasal formulation [82].

Part 11: A Shift in Psychiatric Discourse

The „psychedelic renaissance" necessitates a move away from the „broken brain" narrative toward a model of nervous system resilience and emotional integration.

11.1. Trauma as a Process: The MDMA Precedent

The shift from asking „What is wrong with you?" to „What happened to you?" is most evident in the clinical success of MDMA-assisted therapy for PTSD [83]. MDMA acts as a catalyst for the therapeutic processing. By reducing amygdala activity while increasing prefrontal cortex engagement, it creates a „window of tolerance” where traumatic memories can be processed without becoming overwhelming [84].

11.2. The Democratization of Mental Health

The vision of a future where psychedelic-assisted therapy (PAP) is integrated into public health systems faces significant structural barriers. Transitioning from elite private clinics to the National Health Fund (NFZ) model requires a strategic approach to training and regulation [77].

Summary

We are standing at the threshold of a fundamental change in psychiatry. For the first time, we are moving away from the „maintenance model" of daily medication toward an interventional model that seeks to address the root causes of mental distress [85].

Although the path to widespread accessibility of these methods in Poland remains long and fraught with legislative hurdles, the scientific data is unequivocal. The brain possesses an extraordinary capacity for regeneration—it only needs the right biological impulse and therapeutic suport [65]. Professor David Nutt claimed UN conventions on drugs in the 1960s and 1970s have delayed the development of „innovative treatments” for PTSD and depression by 30 years and also set back research into areas of neuroscience such as consciousness. He also called it „the worst case of scientific censorship” [86]. Maybe the time has come for the science to stop being afraid of the tools it has discovered itself?

All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding

Data availability statement: Data sharing is not applicable to this article

Conflict of interest: The authors declare no conflict of interest

Declaration of the use of generative AI and AI-assisted technologies in the writing process: The authors did not utilize any AI-powered software or assistant in the development of the research design, analysis, interpretation, or overall preparation of this manuscript. All content, ideas, and intellectual contributions are solely the responsibility of the authors. In preparing this work, the authors used generative AI tools (ChatGPT) solely to support language editing and text formatting. After using these tools, the authors reviewed and edited the text as needed and accepted full responsibility for the content of the publication. AI tools were used exclusively for grammar checking and language refinement.

REFERENCES

1. Rybakowski, J. (2025). Sixty years of neurotransmitter concepts of mood disorders. Sześćdziesiąt lat neuroprzekaźnikowych koncepcji chorób afektywnych. *Psychiatria Polska, 59*(5), 707–720. https://doi.org/10.12740/PP/205845
2. Schildkraut, J. J. (1965). The catecholamine hypothesis of affective disorders: A review of supporting evidence. *The American Journal of Psychiatry, 122*(5), 509–522. https://doi.org/10.1176/ajp.122.5.509
3. Müller-Oerlinghausen, B., & Abou-Saleh, M. T. (2019). Alec J. Coppen—A pioneering psychiatrist who discovered the pivotal role of serotonin in the pathogenesis of depression as well as the antisuicidal effect of lithium. *International Journal of Bipolar Disorders, 7*(1), Article 15. https://doi.org/10.1186/s40345-019-0150-3
4. Harmer, C. J., Duman, R. S., & Cowen, P. J. (2017). How do antidepressants work? New perspectives for refining future treatment approaches. *The Lancet Psychiatry, 4*(5), 409–418. https://doi.org/10.1016/S2215-0366(17)30015-9
5. Wong, D. T., Horng, J. S., Bymaster, F. P., Hauser, K. L., & Molloy, B. B. (1974). A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. *Life Sciences, 15*(3), 471–479. https://doi.org/10.1016/0024-3205(74)90345-2
6. World Health Organization. (2025, August 29). *Depressive disorder (depression).* https://www.who.int/news-room/fact-sheets/detail/depression
7. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. (2017). Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. *The Lancet, 390*(10100), 1211–1259. https://doi.org/10.1016/S0140-6736(17)32154-2
8. Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., McGrath, P. J., Rosenbaum, J. F., Sackeim, H. A., Kupfer, D. J., Luther, J., & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. *The American Journal of Psychiatry, 163*(11), 1905–1917. https://doi.org/10.1176/ajp.2006.163.11.1905
9. Al-Harbi, K. S. (2012). Treatment-resistant depression: Therapeutic trends, challenges, and future directions. *Patient Preference and Adherence, 6*, 369–388. https://doi.org/10.2147/PPA.S29716
10. Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., & Horowitz, M. A. (2022). The serotonin theory of depression: A systematic umbrella review of the evidence. *Molecular Psychiatry, 28*, 3243–3256. https://doi.org/10.1038/s41380-022-01661-0
11. Plöderl, M., Lyus, R., Horowitz, M. A., & Moncrieff, J. (2025). The loss of efficacy of fluoxetine in pediatric depression: Explanations, lack of acknowledgment, and implications for other treatments. *Journal of Clinical Epidemiology*, Article 112016. https://doi.org/10.1016/j.jclinepi.2025.112016
12. Aftab, A. (2022, November 20). *The case for antidepressants in 2022.* Psychiatry at the Margins. https://www.psychiatrymargins.com/p/the-case-for-antidepressants-in-2022
13. Castrén, E., & Monteggia, L. M. (2021). Brain-derived neurotrophic factor signaling in depression and antidepressant action. *Biological Psychiatry, 90*(2), 128–136. https://doi.org/10.1016/j.biopsych.2021.05.008
14. Taylor, J. R., DiLeone, R. J., & Picciotto, M. R. (2020). Ronald S. Duman, PhD (1954–2020). *Nature Neuroscience, 23*(5), 595. https://doi.org/10.1038/s41593-020-0629-3
15. McEwen, B. S. (2016). Stress-induced remodeling of hippocampal CA3 pyramidal neurons. *Brain Research, 1645*, 50–54. https://doi.org/10.1016/j.brainres.2015.12.043
16. Moliner, R., Girych, M., Brunello, C. A., Kovaleva, V., Biojone, C., Enkavi, G., Antenucci, L., Kot, E. F., Goncharuk, S. A., Kaurinkoski, K., Kuutti, M., Fred, S. M., Elsilä, L. V., Sakson, S., Cannarozzo, C., Diniz, C. R. A. F., Seiffert, N., Rubiolo, A., Haapaniemi, H., Meshi, E., et al. (2023). Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. *Nature Neuroscience, 26*(6), 1032–1041. https://doi.org/10.1038/s41593-023-01316-5

17. Azarias, F. R., Almeida, G. H. D. R., de Melo, L. F., Rici, R. E. G., & Maria, D. A. (2025). The journey of the default mode network: Development, function, and impact on mental health. *Biology, 14*(4), Article 395. https://doi.org/10.3390/biology14040395
18. Katayama, N., Shinagawa, K., Hirano, J., Kobayashi, Y., Nakagawa, A., Umeda, S., Kamiya, K., Tajima, M., Amano, M., Nogami, W., Ihara, S., Noda, S., Terasawa, Y., Kikuchi, T., Mimura, M., & Uchida, H. (2025). Dynamic neural network modulation associated with rumination in major depressive disorder: A prospective observational comparative analysis of cognitive behavioral therapy and pharmacotherapy. *Translational Psychiatry, 15*(1). https://doi.org/10.1038/s41398-025-03489-y
19. Hamilton, J. P., Farmer, M., Fogelman, P., & Gotlib, I. H. (2015). Depressive rumination, the default-mode network, and the dark matter of clinical neuroscience. *Biological Psychiatry, 78*(4), 224–230. https://doi.org/10.1016/j.biopsych.2015.02.020
20. Carhart-Harris, R. L. (2018). The entropic brain—Revisited. *Neuropharmacology, 142*, 167–178. https://doi.org/10.1016/j.neuropharm.2018.03.010
21. Gattuso, J. J., Perkins, D., Ruffell, S., Lawrence, A. J., Hoyer, D., Jacobson, L. H., Timmermann, C., Castle, D., Rossell, S. L., Downey, L. A., Pagni, B. A., Galvão-Coelho, N. L., Nutt, D., & Sarris, J. (2023). Default mode network modulation by psychedelics: A systematic review. *The International Journal of Neuropsychopharmacology, 26*(3), 155–188. https://doi.org/10.1093/ijnp/pyac074
22. Hofmann, A. (2019). *LSD, my problem child; and, Insights/outlooks.* Beckley Foundation.
23. Osmond, H. (1957). A review of the clinical effects of psychotomimetic agents. *Annals of the New York Academy of Sciences, 66*(3), 418–434. https://doi.org/10.1111/j.1749-6632.1957.tb40738.x
24. Grof, S. (1979). *Realms of the human unconscious: Observations from LSD research.* Souvenir Press.
25. Krebs, T. S., & Johansen, P. Ø. (2012). Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. *Journal of Psychopharmacology, 26*(7), 994–1002. https://doi.org/10.1177/0269881112439253
26. Gałecki, P., Szulc, A., & Urban, E. (2023). *Psychiatria.* Edra Urban & Partner.
27. Reither, E. J. (2025). *The Harvard Psilocybin Project 1960–1963.*
28. Belouin, S. J., & Henningfield, J. E. (2018). Psychedelics: Where we are now, why we got here, what we must do. *Neuropharmacology, 142*, 7–19. https://doi.org/10.1016/j.neuropharm.2018.02.018
29. Nutt, D. J. (2025). Drug development in psychiatry: 50 years of failure and how to resuscitate it. *The Lancet Psychiatry, 12*(3), 228–238. https://doi.org/10.1016/S2215-0366(24)00370-5
30. Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024). Ketamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms. *Neuropsychopharmacology, 49*, 41–50. https://doi.org/10.1038/s41386-023-01629-w
31. Reber, A. (2016). Airway characteristics and safe management of spontaneously breathing patients: Risks of sedation and analgesia and changes in wakefulness. *International Journal of Clinical Medicine, 7*(11), 726–735. https://doi.org/10.4236/ijcm.2016.711079
32. McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., Iosifescu, D. V., Lopez Jaramillo, C., Kasper, S., Kratiuk, K., Lee, J. G., Lee, Y., Lui, L. M. W., Mansur, R. B., Papakostas, G. I., Subramaniapillai, M., et al. (2021). Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. *The American Journal of Psychiatry, 178*(5), 383–399. https://doi.org/10.1176/appi.ajp.2020.20081251
33. Rang, H., Dale, M., Ritter, J., Flower, R., & Henderson, G. (2020). *Rang and Dale's pharmacology* (9th ed., Polish ed., pp. 578–579, 667). Elsevier Churchill Livingstone; Edra Urban & Partner.
34. Zanos, P., & Gould, T. D. (2018). Mechanisms of ketamine action as an antidepressant. *Molecular Psychiatry, 23*(4), 801–811. https://doi.org/10.1038/mp.2017.255
35. Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016). Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. *Nature Medicine, 22*(3), 238–249. https://doi.org/10.1038/nm.4050
36. Pothula, S., Kato, T., Liu, R. J., Wu, M., Gerhard, D., Shinohara, R., Sliby, A. N., Chowdhury, G. M. I., Behar, K. L., Sanacora, G., Banerjee, P., & Duman, R. S. (2021). Cell-type specific modulation of NMDA receptors triggers antidepressant actions. *Molecular Psychiatry, 26*(9), 5097–5111. https://doi.org/10.1038/s41380-020-0796-3
37. Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997). Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. *The Journal of Neuroscience, 17*(8), 2921–2927. https://doi.org/10.1523/jneurosci.17-08-02921.1997
38. Anand, A., Mathew, S. J., Sanacora, G., Murrough, J. W., Goes, F. S., Altinay, M., Aloysi, A. S., Asghar-Ali, A. A., Barnett, B. S., Chang, L. C., Collins, K. A., Costi, S., Iqbal, S., Jha, M. K., Krishnan, K., Malone, D. A., Nikayin, S., Nissen, S. E., Ostroff, R. B., et al. (2023). Ketamine versus ECT for nonpsychotic treatment-resistant major depression. *The New England Journal of Medicine, 388*(25), 2315–2325. https://doi.org/10.1056/NEJMoa2302399

39. Li, N., Lee, B., Liu, R. J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X. Y., Aghajanian, G., & Duman, R. S. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. *Science, 329*(5994), 959–964. https://doi.org/10.1126/science.1190287
40. Park, H., & Poo, M. M. (2013). Neurotrophin regulation of neural circuit development and function. *Nature Reviews Neuroscience, 14*(1), 7–23. https://doi.org/10.1038/nrn3379
41. Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P. F., Kavalali, E. T., & Monteggia, L. M. (2011). NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. *Nature, 475*(7354), 91–95. https://doi.org/10.1038/nature10130
42. Duman, R. S., & Monteggia, L. M. (2006). A neurotrophic model for stress-related mood disorders. *Biological Psychiatry, 59*(12), 1116–1127. https://doi.org/10.1016/j.biopsych.2006.02.013
43. Casarotto, P. C., Girych, M., Fred, S. M., Kovaleva, V., Moliner, R., Enkavi, G., Biojone, C., Cannarozzo, C., Sahu, M. P., Kaurinkoski, K., Brunello, C. A., Steinzeig, A., Winkel, F., Patil, S., Vestring, S., Serchov, T., Diniz, C. R. A. F., Laukkanen, L., Cardon, I., Antila, H., et al. (2021). Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. *Cell, 184*(5), 1299–1313.e19. https://doi.org/10.1016/j.cell.2021.01.034
44. Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., & Drevets, W. C. (2018). Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial. *JAMA Psychiatry, 75*(2), 139–148. https://doi.org/10.1001/jamapsychiatry.2017.3739
45. Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Curran, H. V., & Nutt, D. J. (2018). Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. *Psychopharmacology, 235*(2), 399–408. https://doi.org/10.1007/s00213-017-4771-x
46. Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. *Journal of Psychopharmacology, 30*(12), 1181–1197. https://doi.org/10.1177/0269881116675513
47. Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. *Nature Reviews Neuroscience, 11*(9), 642–651. https://doi.org/10.1038/nrn2884
48. Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., Hobden, P., Evans, J., Feilding, A., Wise, R. G., & Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. *Proceedings of the National Academy of Sciences of the United States of America, 109*(6), 2138–2143. https://doi.org/10.1073/pnas.1119598109
49. Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V. H., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. *The Lancet Psychiatry, 3*(7), 619–627. https://doi.org/10.1016/S2215-0366(16)30065-7
50. Meunier, D., Lambiotte, R., & Bullmore, E. T. (2010). Modular and hierarchically modular organization of brain networks. *Frontiers in Neuroscience, 4*, Article 200. https://doi.org/10.3389/fnins.2010.00200
51. Petri, G., Expert, P., Turkheimer, F., Carhart-Harris, R., Nutt, D., Hellyer, P. J., & Vaccarino, F. (2014). Homological scaffolds of brain functional networks. *Journal of the Royal Society Interface, 11*(101), Article 20140873. https://doi.org/10.1098/rsif.2014.0873
52. Mithoefer, M. C., Mithoefer, A. T., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., Holland, J., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2018). 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: A randomised, double-blind, dose-response, phase 2 clinical trial. *The Lancet Psychiatry, 5*(6), 486–497. https://doi.org/10.1016/S2215-0366(18)30135-4
53. Phelps, J. (2017). Developing guidelines and competencies for the training of psychedelic therapists. *Journal of Humanistic Psychology, 57*(5), 450–487. https://doi.org/10.1177/0022167817711304
54. Johnson, M., Richards, W., & Griffiths, R. (2008). Human hallucinogen research: Guidelines for safety. *Journal of Psychopharmacology, 22*(6), 603–620. https://doi.org/10.1177/0269881108093587
55. Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., Molero, P., Vieta, E., Bajbouj, M., Manji, H., Drevets, W. C., & Singh, J. B. (2019). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study. *The American Journal of Psychiatry, 176*(6), 428–438. https://doi.org/10.1176/appi.ajp.2019.19020172
56. Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & American Psychiatric Association Council of Research Task Force on Novel Biomarkers and Treatments. (2017). A consensus statement on the use of ketamine in the treatment of mood disorders. *JAMA Psychiatry, 74*(4), 399–405. https://doi.org/10.1001/jamapsychiatry.2017.0080

57. Halpern, J. H., & Pope, H. G., Jr. (2003). Hallucinogen persisting perception disorder: What do we know after 50 years? *Drug and Alcohol Dependence, 69*(2), 109–119. https://doi.org/10.1016/s0376-8716(02)00306-x
58. Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. *Journal of Psychopharmacology, 30*(12), 1268–1278. https://doi.org/10.1177/0269881116662634
59. Szigeti, B., Weiss, B., Rosas, F. E., Erritzoe, D., Nutt, D., & Carhart-Harris, R. (2024). Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression. *Psychological Medicine, 54*(8), 1717–1724. https://doi.org/10.1017/S0033291723003653
60. Price, J., Cole, V., & Goodwin, G. M. (2009). Emotional side-effects of selective serotonin reuptake inhibitors: Qualitative study. *The British Journal of Psychiatry, 195*(3), 211–217. https://doi.org/10.1192/bjp.bp.108.051110
61. Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression. *The New England Journal of Medicine, 384*(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994
62. Serretti, A., & Chiesa, A. (2009). Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis. *Journal of Clinical Psychopharmacology, 29*(3), 259–266. https://doi.org/10.1097/JCP.0b013e3181a5233f
63. Gafoor, R., Booth, H. P., & Gulliford, M. C. (2018). Antidepressant utilisation and incidence of weight gain during 10 years' follow-up: Population based cohort study. *BMJ, 361*, Article k1951. https://doi.org/10.1136/bmj.k1951
64. Goldberg, S. B., Pace, B. T., Nicholas, C. R., Raison, C. L., & Hutson, P. R. (2020). The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. *Psychiatry Research, 284*, Article 112749. https://doi.org/10.1016/j.psychres.2020.112749
65. Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., Duim, W. C., Dennis, M. Y., McAllister, A. K., Ori-McKenney, K. M., Gray, J. A., & Olson, D. E. (2018). Psychedelics promote structural and functional neural plasticity. *Cell Reports, 23*(11), 3170–3182. https://doi.org/10.1016/j.celrep.2018.05.022
66. Davis, A. K., & Griffiths, R. R. (2021). Errors in a response rate and in effect sizes in study of psilocybin-assisted therapy for major depressive disorder. *JAMA Psychiatry*. https://doi.org/10.1001/jamapsychiatry.2020.4638
67. Rhead, J. (2014). The psychedelic explorer's guide: Safe, therapeutic, and sacred journeys. *Journal of Psychoactive Drugs, 46*(4), 347–348. https://doi.org/10.1080/02791072.2014.948329
68. Szigeti, B., Kartner, L., Blemings, A., Rosas, F., Feilding, A., Nutt, D. J., Carhart-Harris, R. L., & Erritzoe, D. (2021). Self-blinding citizen science to explore psychedelic microdosing. *eLife, 10*, Article e62878. https://doi.org/10.7554/eLife.62878
69. Trautmann, S., Rehm, J., & Wittchen, H. U. (2016). The economic costs of mental disorders: Do our societies react appropriately to the burden of mental disorders? *EMBO Reports, 17*(9), 1245–1249. https://doi.org/10.15252/embr.201642951
70. Greenberg, P., Chitnis, A., Louie, D., Suthoff, E., Chen, S. Y., Maitland, J., Gagnon-Sanschagrin, P., Fournier, A. A., & Kessler, R. C. (2023). The economic burden of adults with major depressive disorder in the United States (2019). *Advances in Therapy, 40*(10), 4460–4479. https://doi.org/10.1007/s12325-023-02622-x
71. Therapeutic Goods Administration. (2023, February 3). *Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists.* https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists
72. Oregon Health Authority. (n.d.). *Oregon Psilocybin Services.* State of Oregon. https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Pages/Oregon-Psilocybin-Services.aspx
73. Amabile, J., & Fenberg, S. (n.d.). *Natural medicine regulation and legalization.* Colorado General Assembly. https://leg.colorado.gov/bills/sb23-290
74. *Ustawa z dnia 29 lipca 2005 r. o przeciwdziałaniu narkomanii.* (n.d.). Internetowy System Aktów Prawnych. https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=wdu20051791485
75. Ministerstwo Zdrowia. (2024). *Obwieszczenie Ministra Zdrowia z dnia 18 marca 2024 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na 1 kwietnia 2024 r.* https://www.gov.pl/web/zdrowie/obwieszczenie-ministra-zdrowia-z-dnia-18-marca-2024-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywieniowego-oraz-wyrobow-medycznych
76. Medexpress.pl. (2026). *B.147. nowy od 07-2023* [Word document]. https://www.medexpress.pl/documents/73/B.147._nowy_od_07-2023.docx
77. European Medicines Agency. (2023, December 18). *EMA multi-stakeholder workshop on psychedelics—Towards an EU regulatory framework.* https://www.ema.europa.eu/en/events/ema-multi-stakeholder-workshop-psychedelics-towards-eu-regulatory-framework#event-summary-64458
78. Cameron, L. P., Tombari, R. J., Lu, J., Pell, A. J., Hurley, Z. Q., Ehinger, Y., Vargas, M. V., McCarroll, M. N., Taylor, J. C., Myers-Turnbull, D., Liu, T., Yaghoobi, B., Laskowski, L. J., Anderson, E. I., Zhang, G., Viswanathan, J., Brown, B. M., Tjia, M., Dunlap, L. E., & Rabow, Z. T. (2020). A non-hallucinogenic psychedelic analogue with therapeutic potential. *Nature, 589*, 474–479. https://doi.org/10.1038/s41586-020-3008-z
79. Olson, D. E. (2018). Psychoplastogens: A promising class of plasticity-promoting neurotherapeutics. *Journal of Experimental Neuroscience, 12*, Article 1179069518800508. https://doi.org/10.1177/1179069518800508

80. Yaden, D. B., & Griffiths, R. R. (2020). The subjective effects of psychedelics are necessary for their enduring therapeutic effects. *ACS Pharmacology & Translational Science, 4*(2), 568–572. https://doi.org/10.1021/acsptsci.0c00194
81. Uthaug, M. V., Lancelotta, R., van Oorsouw, K., Kuypers, K. P. C., Mason, N., Rak, J., Šuláková, A., Jurok, R., Maryška, M., Kuchař, M., Páleníček, T., Riba, J., & Ramaekers, J. G. (2019). A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. *Psychopharmacology, 236*(9), 2653–2666. https://doi.org/10.1007/s00213-019-05236-w
82. Reckweg, J. T., Uthaug, M. V., Szabo, A., Davis, A. K., Lancelotta, R., Mason, N. L., & Ramaekers, J. G. (2022). The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). *Journal of Neurochemistry, 162*(1), 128–146. https://doi.org/10.1111/jnc.15587
83. Milton, H. (2022). Books: *What happened to you? Conversations on trauma, resilience, and healing. British Journal of General Practice, 72*(716), 125. https://doi.org/10.3399/bjgp22x718709
84. Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot'alora G, M., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., Tzarfaty, K., et al. (2023). MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. *Focus, 21*(3), 315–328. https://doi.org/10.1176/appi.focus.23021011
85. Carhart-Harris, R. L., & Goodwin, G. M. (2017). The therapeutic potential of psychedelic drugs: Past, present, and future. *Neuropsychopharmacology, 42*(11), 2105–2113. https://doi.org/10.1038/npp.2017.84
86. Cooper, C. (2013, June 12). "The worst case of scientific censorship since the Catholic Church banned the works of Galileo": Scientists call for drugs to be legalised to allow proper study of their properties. *The Independent.* https://www.independent.co.uk/news/science/the-worst-case-of-scientific-censorship-since-the-catholic-church-banned-the-works-of-galileo-scientists-call-for-drugs-to-be-legalised-to-allow-proper-study-of-their-properties-8654514.html